Proteomics International Laboratories (ASX: PIQ) has obtained what it describes as “groundbreaking” results in its development of treatments for deadly
Proteomics International Laboratories has engaged Growth Medics B.V., to assist with the selection of EU alliance partners for its PromarkerD predictive test for diabetic kidney disease.
Proteomics International Laboratories Ltd , a pioneer in predictive diagnostics, is pleased to announce it has signed a Material Transfer Agreement with the globally-respected University of Oxford to...
Proteomics International Laboratories Ltd continues to work diligently toward a national launch in the United States of America, of PromarkerD, the Company's innovative predictive test for diabetic...
Proteomics International Laboratories (ASX: PIQ) has announced that its subsidiary, OxiDx, has secured a patent across 19 major European countries for its platform technology designed to assess oxidative stress.
Proteomics International Laboratories Ltd is pleased to announce that the US Centers for Medicare & Medicaid Services has published its final determination of the national reimbursement price in the...